Brief: Gossamer Bio Q2 EPS USD -0.17

Gossamer Bio

05/08/2025 21:01

Overview

Gossamer Bio Q2 revenue drops to $11.5 mln from $95.8 mln yr/yr

Net loss for Q2 2025 at $38.3 mln, impacted by absence of one-time license revenue

Topline results from Phase 3 PROSERA Study expected in February 2026

Outlook

Gossamer Bio expects topline PROSERA Study results in February 2026

Company plans first site activations for SERANATA Study in Q4 2025

Gossamer Bio expects cash reserves to fund operations into 2027

Result Drivers

REVENUE DECLINE - Co attributes revenue drop to absence of one-time license revenue from collaboration with Chiesi

CLINICAL TRIALS - Completion of enrollment for Phase 3 PROSERA Study in PAH patients

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.17
Q2 Net Income
-$38.27 mln
Q2 Basic EPS
-$0.17
Q2 Operating Expenses
$50.25 mln
Q2 Operating Income
-$38.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Gossamer Bio Inc is $8.00, about 72.9% above its August 4 closing price of $2.17

Press Release: ID:nBw4p947Ba

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)